1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection

BACKGROUND: ME1100 (arbekacin inhalational solution) is an inhaled aminoglycoside being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). PK-PD target attainment analyses were undertaken to evaluate ME1100 regimens for pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhavnani, Sujata M, Hammel, Jeffrey P, Lakota, Elizabeth A, VanScoy, Brian D, Nagira, Yu, Rubino, Christopher M, Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252562/
http://dx.doi.org/10.1093/ofid/ofy210.1223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252562/
http://dx.doi.org/10.1093/ofid/ofy210.1223

Ejemplares similares